central bank digital currency china Top Related searches

Guoxuan Hi-Tech: China, the strategic shareholder, continued to give up voting rights. Guoxuan Hi-Tech announced that Guoxuan Holdings, Li Zhen and Jerry Lee (collectively referred to as the "founding shareholders") and China, the strategic shareholder of the company, signed a Supplementary Agreement on the Shareholders' Agreement of Guoxuan Hi-Tech Co., Ltd., and Volkswagen China agreed to extend the commitment period of giving up voting rights. That is to say, within 72 months after the relevant shares of the company involved in the non-public offering and share transfer are registered in the name of Volkswagen China or within a longer period determined by Volkswagen China, it will irrevocably give up the voting rights of some of its shares in the company, so that the voting rights of Volkswagen China will be at least 5% lower than that of the founding shareholder. Volkswagen China's extension of the period of giving up its voting rights commitment this time will not lead to the change of the company's control rights and will not affect the normal production and operation of the company. Mr. Li Zhen remains the actual controller of the company.Market News: The Slovak Prime Minister said that Slovakia supports the normalization of relations between Russia and western countries and opposes the emergence of a new iron curtain in Europe. The Slovak Prime Minister emphasized that all conflicts will be finally resolved through negotiations.The United States ITC issued a 337-part final ruling on the wireless front-end module and its downstream equipment. According to the China Trade Relief Information Network, on December 10, 2024, the United States International Trade Commission (ITC) issued a notice saying that it made a 337-part final ruling on a specific wireless front-end module and its downstream equipment: the preliminary ruling (No.13) made by the administrative judge in this case on November 8, 2024 will not be reviewed, that is, based on the withdrawal of the applicant, Kangxi Communication Technology (Shanghai) Co., Ltd. and Ruijie Network Co., Ltd. are listed as defendants.

Zhongzhiwei Technology completed tens of millions of yuan financing. On December 12th, Nanjing Zhongzhiwei Information Technology Co., Ltd. (Zhongzhiwei Technology) completed tens of millions of yuan B1 financing, which was jointly invested by Guangzhou Baiyun Financial Holding Group Co., Ltd. and Beijing Hongfeng Private Equity Fund Management Co., Ltd. This round of financing funds will be used for iterative application of AI+ network security products, breakthrough in key industry landing scenarios and market channel construction. Zhongzhiwei Technology is a solution provider of "city-level data+digital security operation", and has launched a series of new platform-based network security products around AISecOps (artificial intelligence security operation).Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).The downtime lasted more than 4 hours, and the failure of ChatGPT and Sora services has been fully repaired. On the afternoon of December 12, Beijing time, OpenAI updated the accident report and said that API, ChatGPT and Sora services have now fully resumed operation. Earlier today, OpenAI confirmed that ChatGPT, its chat robot, experienced a worldwide downtime, and Sora and API were also affected. It is understood that the fault lasted about 4 hours and 10 minutes. OpenAI said that it will conduct a comprehensive root cause analysis of this failure.

On December 11th, it was reported that the U.S. government was divided over the U.S. steel acquisition, and Biden considered blocking the transaction. It was reported that the U.S. Department of Defense, the Ministry of Finance and the State Council all believed that the Japanese Steel Company's $15 billion acquisition of American steel companies would not bring national security risks, but U.S. President Biden was expected to block the transaction. Earlier, some media quoted people familiar with the matter as saying that Biden planned to block the acquisition of American steel companies later this month on the grounds of national security. The Committee on Foreign Investment in the United States has been reviewing the proposed acquisition for most of this year, and the group must submit its decision to Biden before December 22 or 23.The Bank of Japan's short-term survey may show that business confidence has hardly changed. It is reported that the short-term survey released by the Bank of Japan on Friday may show that the mood of large manufacturers has remained almost unchanged in the last quarter under the influence of complex signals such as the recovery of the automobile industry and concerns about the global economic slowdown. Economists surveyed by data provider Quick predict that the prosperity judgment index of large-scale manufacturing industry will be +12, compared with +13 in the last survey. The survey is closely watched for clues about the decision of the Bank of Japan at its meeting next week. If it shows strong capital expenditure plan, high inflation expectation and tight employment situation, it may support the idea of raising interest rates early.Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).